Replimune Group Inc

NASDAQ REPL

Data sourced from

and

Download Data

Replimune Group Inc Days Payable Outstanding (DPO) 3 year CAGR for the year ending March 31, 2024: 19.50%

Replimune Group Inc Days Payable Outstanding (DPO) 3 year CAGR is 19.50% for the year ending March 31, 2024, a 300.06% change year over year. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Replimune Group Inc Days Payable Outstanding (DPO) for the year ending March 31, 2023 was 800.11, a 168.72% change year over year.
Replimune Group Inc Days Payable Outstanding (DPO) for the year ending March 31, 2022 was 297.74, a 43.37% change year over year.
Replimune Group Inc Days Payable Outstanding (DPO) for the year ending March 31, 2021 was 207.68, a -70.06% change year over year.
Replimune Group Inc Days Payable Outstanding (DPO) for the year ending March 31, 2020 was 693.64.

NASDAQ: REPL

Replimune Group Inc

CEO	Mr. Philip Astley-Sparke FSA
IPO Date	July 20, 2018
Location	United States
Headquarters	500 Unicorn Park Drive, Woburn, MA, United States, 01801
Employees	331
Sector	Healthcare
Industry	Biotechnology

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key trends